A nomogram for predicting cancer-specific survival in patients with locally advanced unresectable esophageal cancer: development and validation study

被引：0

作者：

Xie, Liangyun ^{[1
]}

Zhang, Yafei ^{[1
]}

Niu, Xiedong ^{[1
]}

Jiang, Xiaomei ^{[2
]}

Kang, Yuan ^{[1
]}

Diao, Xinyue ^{[1
]}

Fang, Jinhai ^{[1
]}

Yu, Yilin ^{[1
]}

Yao, Jun ^{[1
]}

机构：

[1] Henan Univ Sci & Technol, Affiliated Hosp 1, Coll Clin Med, Luoyang, Peoples R China

[2] North China Univ Sci & Technol, Affiliated Tangshan Gongren Hosp, Tangshan, Peoples R China

来源：

FRONTIERS IN IMMUNOLOGY | 2025年 / 16卷

关键词：

locally advanced esophageal cancer; SEER; cancer-specific survival (CSS); prognostic nomogram; LASSO regression; immune microenvironment; SQUAMOUS-CELL CARCINOMA; PROGNOSIS; CHEMORADIOTHERAPY;

D O I：

10.3389/fimmu.2025.1524439

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Background Immunotherapy research for esophageal cancer is progressing rapidly, particularly for locally advanced unresectable cases. Despite these advances, the prognosis remains poor, and traditional staging systems like AJCC inadequately predict outcomes. This study aims to develop and validate a nomogram to predict cancer-specific survival (CSS) in these patients.Methods Clinicopathological and survival data for patients diagnosed between 2010 and 2021 were extracted from the Surveillance, Epidemiology, and End Results (SEER) database. Patients were divided into a training cohort (70%) and a validation cohort (30%). Prognostic factors were identified using the Least Absolute Shrinkage and Selection Operator (LASSO) regression. A nomogram was constructed based on the training cohort and evaluated using the concordance index (C-index), net reclassification improvement (NRI), integrated discrimination improvement (IDI), calibration plots, and area under the receiver operating characteristic curve (AUC). Kaplan-Meier survival curves were used to validate the prognostic factors.Results The study included 4,258 patients, and LASSO-Cox regression identified 10 prognostic factors: age, marital status, tumor location, tumor size, pathological grade, T stage, American Joint Committee on Cancer (AJCC) stage, SEER stage, chemotherapy, and radiotherapy. The nomogram achieved a C-index of 0.660 (training set) and 0.653 (validation set), and 1-, 3-, and 5-year AUC values exceeded 0.65. Calibration curves showed a good fit, and decision curve analysis (DCA), IDI, and NRI indicated that the nomogram outperformed traditional AJCC staging in predicting prognosis.Conclusions We developed and validated an effective nomogram model for predicting CSS in patients with locally advanced unresectable esophageal cancer. This model demonstrated significantly superior predictive performance compared to the traditional AJCC staging system. Future research should focus on integrating emerging biomarkers, such as PD-L1 expression and tumor mutational burden (TMB), into prognostic models to enhance their predictive accuracy and adapt to the evolving landscape of immunotherapy in esophageal cancer management.

引用

页数：16

共 66 条

[1] Bray F., Laversanne M., Sung H., Ferlay J., Siegel R.L., Soerjomataram I., Et al., Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries, CA Cancer J Clin, 74, (2024)
[2] Xie R., Cai Q., Chen T., Huang H., Chen C., Current and future on definitive concurrent chemoradiotherapy for inoperable locally advanced esophageal squamous cell carcinoma, Front Oncol, 14, (2024)
[3] Shah M.A., Hofstetter W.L., Kennedy E.B., Immunotherapy in patients with locally advanced esophageal carcinoma: ASCO treatment of locally advanced esophageal carcinoma guideline rapid recommendation update, J Clin Oncol: Off J Am Soc Clin Oncol, 39, (2021)
[4] Wang F.M., Mo P., Yan X., Lin X.Y., Fu Z.C., Present situation and prospect of immunotherapy for unresectable locally advanced esophageal cancer during peri-radiotherapy, World J Gastrointest Oncol, 16, pp. 1-7, (2024)
[5] Olawaiye A.B., Baker T.P., Washington M.K., Mutch D.G., The new (Version 9) American Joint Committee on Cancer tumor, node, metastasis staging for cervical cancer, CA Cancer J Clin, 71, (2021)
[6] Fan C., Wang X., Zheng X., Sun Y., Ye K., Jiang Y., Et al., Consolidation chemotherapy after definitive concurrent chemoradiotherapy in patients with inoperable esophageal squamous cell carcinoma: a multicenter non-inferiority phase III randomized clinical trial, BMC Cancer, 24, (2024)
[7] Al-Kaabi A., Schoon E.J., Deprez P.H., Seewald S., Groth S., Giovannini M., Et al., Salvage endoscopic resection after definitive chemoradiotherapy for esophageal cancer: a Western experience, Gastrointestinal Endoscopy, 93, pp. 888-898.e1, (2021)
[8] Balachandran V.P., Gonen M., Smith J.J., DeMatteo R.P., Nomograms in oncology: more than meets the eye, Lancet Oncol, 16, (2015)
[9] Che W.Q., Li Y.J., Tsang C.K., Wang Y.J., Chen Z., Wang X.Y., Et al., How to use the Surveillance, Epidemiology, and End Results (SEER) data: research design and methodology, Military Med Res, 10, (2023)
[10] Xie L., Zhang Z., Survival benefit of combined immunotherapy and chemoradiotherapy in locally advanced unresectable esophageal cancer: an analysis based on the SEER database, Front Immunol, 15, (2024)

← 1 2 3 4 5 6 7 →